scholarly journals A direct healthcare cost analysis of the cryopreserved versus fresh transfer policy at the blastocyst stage

2017 ◽  
Vol 34 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Enrico Papaleo ◽  
Luca Pagliardini ◽  
Valeria Stella Vanni ◽  
Diana Delprato ◽  
Patrizia Rubino ◽  
...  
2018 ◽  
Vol 154 (6) ◽  
pp. S-456
Author(s):  
Jooyoung Lee ◽  
Jihye Kim ◽  
Eun Ae Kang ◽  
hyun jung lee ◽  
Jaeyoung Chun ◽  
...  

2012 ◽  
Vol 73 (S 01) ◽  
Author(s):  
Candace Mitchell ◽  
Adam Zanation ◽  
Brent Senior ◽  
Matthew Ewend ◽  
Charles Ebert

2020 ◽  
Author(s):  
Kanza Aziz ◽  
Bonnielin K. Swenor ◽  
Joseph K. Canner ◽  
Mandeep S. Singh

AbstractImportanceStargardt disease (SD) is the most common juvenile macular degeneration and a leading cause of uncorrectable childhood blindness. The progressive and incurable nature of this chronic condition entails a long-term financial burden on affected individuals. The economic costs of SD have not been characterized in detail.ObjectiveTo estimate the direct healthcare cost of SD.DesignCross-sectional analysis of healthcare claims.ParticipantsPatients with an ICD-9 diagnosis code of SD, non-exudative age-related macular degeneration (AMD), or bilateral sensorineural hearing loss (SHL).MethodsOutpatient administrative claims data from the IBM® MarketScan® Commercial Claims and Encounters Database from 2010 to 2014 were analyzed.Main Outcome MeasureAnnual per-patient direct healthcare cost.ResultsA total of 472,428 patients were analyzed (5,015 SD, 369,750 SHL and 97,663 AMD patients respectively). The payment per year of insurance coverage for SD (median: $105.58, IQR: $50.53-$218.71) was higher than that of SHL (median: $51.01, IQR: $25.66-$121.66, p <0.001) and AMD (median: $76.20, IQR: $38.00-$164.86, p <0.001). When adjusted for covariates, the annual payment for SD was $47.83 higher than SHL (p<0.001) and $17.34 higher than AMD (p<0.001).Conclusions and RelevanceThere is a significant direct healthcare cost associated with SD. The annual per-patient cost of SD was higher than SHL, another condition that causes sensory impairment in people of all ages, and nonexudative AMD which causes a similar pattern of visual loss that typically begins later in life. The total lifetime per-patient cost of SD may exceed that of nonexudative AMD.


2018 ◽  
Vol 48 (1) ◽  
pp. 79-92 ◽  
Author(s):  
G. Kovács ◽  
T. Almási ◽  
A. Millier ◽  
M. Toumi ◽  
M. Horváth ◽  
...  

AbstractPurposeTo provide an overview on the magnitude of the impact of schizophrenia on the healthcare system in Europe and to gain a better understanding on the most important factors influencing the variation of costs.MethodsStudies reporting costs and healthcare utilization among patients with schizophrenia were searched in MEDLINE (via Scopus), EMBASE (via Scopus) and Cochrane Database of Systematic Reviews on 19th January 2017.ResultsTwenty-three studies, from the 1075 references initially identified, were included in this review. The annual cost per patient ranged from €533 in Ukraine to €13,704 in the Netherlands. Notably drug costs contributed to less than 25% of the direct healthcare cost per patient in every country, which might be explained by similar pharmaceutical prices among countries due to the reference pricing system applied in Europe. Inpatient costs were the largest component of health service costs in the majority of the countries. Despite methodological heterogeneity across studies, four major themes could be identified (age, severity of symptoms, continuation of treatment/persistence, hospitalization) that have substantial impact on the costs of schizophrenia.ConclusionsSchizophrenia represents a substantial cost for the healthcare system in Europe driven by the high cost per patient. Substantial savings could potentially be achieved by increasing investment in the following areas: (1) reducing the number of hospitalizations e.g. by increasing the efficiency of outpatient care; (2) working out interventions targeted at specific symptoms; (3) improving patient persistence and adherence in antipsychotic therapy.


2021 ◽  
Author(s):  
Xiaohua Sun ◽  
Jiali Cai ◽  
Lanlan Liu ◽  
Haixiao Chen ◽  
Xiaoming Jiang ◽  
...  

Abstract The embryo position is supposed to affect implantation following embryo transfer. However, embryo dislodging caused by uterine contraction may occurred after transfer. The retrospective study was to investigated whether the factors associated with uterine contractility, such as endometrial thickness and progesterone elevation, affect the association between embryo position and implantation. A total of 7849 fresh transfer cycles on conventional stimulation in a single IVF centre during the period 2013–2015 was reviewed. Patients were categorized according to quartiles of embryo-fundus distance (≤9, 9.1-11, 11.1-14, ≥1.4 mm, respectively). Adjusted for confounding factors, the odds ratio (OR) (95%CI) for clinical pregnancy was 0.90 (0.79-1.02), 0.86 (0.74-0.99) and 0.70 (0.60-0.82) respectively in quartiles 2 through 4, comparing with quartile 1. However, ORs were significantly increased when endometrial thickness was < 8 mm. The ORs comparing quartiles 2 through 4 with quartile 1 increased 1.96 (95%: 1.33-2.90), 1.20 (95%: 0.78-1.87) and 1.98 (95%: 1.20-3.26) fold respectively in cycles with an endometrial thickness < 8 mm than in cycles with a normal endometrial thickness (8-11 mm). Elevated progesterone on the day of hCG and blastocyst stage transfer reduced the ORs. Our data suggested an interaction between patient characteristics and embryo transfer techniques.


2021 ◽  
Vol 27 (1) ◽  
pp. 140-149
Author(s):  
Sarah A. Collier ◽  
Li Deng ◽  
Elizabeth A. Adam ◽  
Katharine M. Benedict ◽  
Elizabeth M. Beshearse ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document